Takeda Pharmaceutical (TAK) Non Operating Income (2019 - 2023)

Takeda Pharmaceutical's Non Operating Income history runs 4 years deep, the most recent figure standing at -$250.2 million for Q1 2023.

• On a quarterly basis, Non Operating Income fell 15.4% year-over-year to -$250.2 million in Q1 2023; TTM through Mar 2023 was -$1.7 billion, a 16.69% decrease from a year earlier, with the FY2023 full-year figure at -$250.2 million, down 11.49% from the prior year.
• Non Operating Income eased to -$250.2 million in Q1 2023 per TAK's latest filing, from -$216.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$0.08 in Q1 2019 and bottomed at -$938.9 million in Q3 2020.
• The 4-year median for Non Operating Income is -$250.2 million (2023), against an average of -$349.9 million.
• Across the five-year window, Non Operating Income sank 439725589405.43% in 2020 and declined 15.4% in 2023, its largest moves.
• Year by year, Non Operating Income stood at -$0.08 in 2019, then slumped by 1201969943408.06% to -$938.9 million in 2020, then jumped by 76.91% to -$216.8 million in 2022, then dropped by 15.4% to -$250.2 million in 2023.
• Per Business Quant, the three latest TAK Non Operating Income figures stand at -$250.2 million (Q1 2023), -$216.8 million (Q1 2022), and -$938.9 million (Q3 2020).